Cantor Fitzgerald Maintains Overweight on BridgeBio Pharma, Raises Price Target to $60
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer maintains an Overweight rating on BridgeBio Pharma (NASDAQ:BBIO) and raises the price target from $50 to $60.
March 11, 2024 | 1:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Josh Schimmer maintains an Overweight rating on BridgeBio Pharma and raises the price target from $50 to $60.
The increase in the price target by a reputable analyst firm like Cantor Fitzgerald suggests a strong bullish outlook on BridgeBio Pharma. This is likely to positively influence investor sentiment and potentially lead to a short-term increase in the stock price. The Overweight rating reaffirms the analyst's confidence in the stock's future performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100